BioXTek
Works in Metabolic & endocrine
BioXTek is a clinical trial sponsor. It has 1 active clinical trial with 30 planned participants, in Metabolic & endocrine. Its FDA record on file shows 1 warning letter.
Trial track record · since 2021
FDA record
Recent FDA actions
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about BioXTek
Yes. FDA has published 1 warning letter naming BioXTek; the latest was posted on 2025-12-09. Each letter links to FDA's own posting.
BioXTek is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 30 planned participants, in Metabolic & endocrine. Since 2021 it has completed 0 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with BioXTek; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-01-08.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with BioXTek.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.